Rivaroxaban 15 mg Tablet
Description
RIVAROOT-15
Rivaroxaban 15 mg Tablets
Division: DIABGLYM
Composition
Each film-coated tablet contains:
Rivaroxaban IP — 15 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Film-coated oral tablet
Product Description
RIVAROOT-15 contains Rivaroxaban 15 mg, a direct oral anticoagulant (DOAC) formulated for the prevention and treatment of thromboembolic disorders. Rivaroxaban is a highly selective direct Factor Xa inhibitor that helps prevent blood clot formation by interrupting the coagulation cascade, thereby reducing the risk of stroke, systemic embolism, deep vein thrombosis (DVT), and pulmonary embolism (PE).
Rivaroxaban 15 mg is widely prescribed in cardiology, vascular medicine, and internal medicine for patients with non-valvular atrial fibrillation, venous thromboembolism, recurrent thrombotic disorders, and those requiring individualized anticoagulation therapy. The 15 mg strength is commonly used during the initial treatment phase of acute DVT and PE and in selected patients with renal impairment requiring dose adjustment. It provides effective anticoagulation with predictable pharmacokinetics and does not require routine INR monitoring in most patients.
RIVAROOT-15 is particularly beneficial for patients with atrial fibrillation at risk of stroke, acute deep vein thrombosis, pulmonary embolism, recurrent venous thromboembolism, and individuals requiring flexible oral anticoagulant dosing.
Technical Knowledge of Rivaroxaban
Rivaroxaban selectively and directly inhibits Factor Xa, a key enzyme in the coagulation cascade responsible for the conversion of prothrombin to thrombin. By reducing thrombin generation, Rivaroxaban prevents fibrin clot formation and thrombus development without directly affecting platelet function.
Rivaroxaban has rapid oral absorption, predictable anticoagulant activity, and a relatively short onset of action. It provides consistent anticoagulation with fixed dosing regimens and has fewer dietary interactions compared with vitamin K antagonists.
Mechanism of Action
Rivaroxaban directly inhibits Factor Xa, reduces thrombin generation, prevents fibrin clot formation, inhibits thrombus development, and reduces the risk of arterial and venous thromboembolic events.
Key Benefits
Effective prevention of stroke in non-valvular atrial fibrillation
Treats acute deep vein thrombosis
Treats pulmonary embolism
Reduces the risk of recurrent venous thromboembolism
Predictable anticoagulant activity
No routine INR monitoring required in most patients
Flexible oral dosing based on clinical indication
Suitable for long-term anticoagulation under medical supervision
Clinical Applications
RIVAROOT-15 is commonly prescribed for stroke prevention in non-valvular atrial fibrillation, initial treatment of deep vein thrombosis, initial treatment of pulmonary embolism, prevention of recurrent DVT and PE, anticoagulation in selected patients with renal impairment, and long-term thromboembolic management.
Facts About Rivaroxaban
Rivaroxaban is one of the most extensively studied direct oral anticoagulants and has strong clinical evidence supporting stroke prevention and venous thromboembolism management. The 15 mg strength is an important therapeutic option for the initial treatment phase of acute thromboembolic disorders and for selected patients requiring dose adjustment based on renal function. Direct Factor Xa inhibition provides effective anticoagulation with a lower burden of monitoring compared with traditional vitamin K antagonists.
Key Facts
Direct oral anticoagulant (DOAC)
Selective Factor Xa inhibitor
Rivaroxaban 15 mg for thromboembolic prevention and treatment
Effective in atrial fibrillation, DVT, and PE
Predictable anticoagulant profile with fixed dosing
Evidence-based anticoagulation therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
RIVAROOT-15 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Vascular Medicine Franchise across India. The increasing prevalence of atrial fibrillation, deep vein thrombosis, pulmonary embolism, cardiovascular disease, and thromboembolic disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose RIVAROOT-15 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Rivaroxaban 15 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
RIVAROOT-15 from DIABGLYM combines effective anticoagulation, comprehensive thromboembolic protection, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, vascular specialists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and advanced Rivaroxaban formulation.
